C.R. Bard upgraded to Overweight from Neutral at JPMorgan JPMorgan upgraded C.R. Bard based on expectations for a resolution of the Gore patent litigation, a positive outcome in the LEVANT 2 trial, and higher earnings revisions. Price target raised to $116 from $110.
News For BCR From The Last 14 Days
Check below for free stories on BCR the last two weeks.
Medtronic data positive for C.R. Bard, says Barclays Barclays said Medtronic's (MDT) better than expected drug coated balloon data could have a positive class effect that benefits C.R. Bard (BCR). The firm reiterates its Overweight rating C.R. Bard and raised its price target to $165 from $160. Note that BofA/Merrill downgraded C.R. Bard to Neutral from Buy following the Medtronic's news.